• 1
    Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 41835.
  • 2
    Soucie JM, Symons J, Evatt B, Brettler D, Huszti H, Linden J. Home-based infusion therapy and hospitalization for bleeding complications among males with hemophilia. Haemophilia 2001; 7: 198206.
  • 3
    Dimichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 527.
  • 4
    Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker RM, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, Dimichele DM, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 53544.
  • 5
    National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Recommendation concerning prophylaxis: regular administration of clotting factor concentrate to prevent bleeding (#179). Accessed 30 August 2012.
  • 6
    Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 464854.
  • 7
    Dsmoszynska A, Kuliczkowski K, Hellmann A, Trelinski J, Kloczko J, Baglin T, Hay C, O’Shaughynessy D, Zaiwlska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C. Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patient with haemophilia A. Hemophilia 2011; 17: 45662.
  • 8
    Klukowska A, Komrska V, Jansen M, Laguna P. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study. Haemophilia 2011; 17: 399406.
  • 9
    Klukowska A, Windyga J, Batorova A. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate®, in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients. Thromb Res 2011; 127: 24753.
  • 10
    Coppola A, Maragaglione M, Santagostino E, Rocino A, Grandone E, Mannucci PM, Di Minno G. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 180915.
  • 11
    Weiss JH, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on post-transfusion and dissociated factor VIII and in patients with von Willebrand disease. J Clin Invest 1977; 60: 390404.
  • 12
    Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 635262.
  • 13
    Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor fVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 772832.
  • 14
    Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies: antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 197884.
  • 15
    Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 2: 959.
  • 16
    Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VII preparations. Haemophilia 1996; 2: 959.
  • 17
    Delignat S, Repessé Y, Navarrete AM, Meslier Y, Gupta N, Christophe OD, Kaveri SV, Lacroix-Demsazes S. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia 2011; 18: 24854.
  • 18
    Dasgupta S, Navarrete AM, Bayry J, Delignat S, Wootla B, Andre S, Christophe O, Nascimbeni M, Jacquemin M, Martinez-Pomares L, Geijtenbeek TB, Morris A, Saint-Remy JM, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci USA 2007; 104: 896570.
  • 19
    Tagariello G, Zanotto D, Radossi  , Sartori R, Belvini D, Salviato R. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Med 2007; 82: 4602.
  • 20
    Salvagno GL, Astermark KJ, Ekman M, Franchini M, Guidi GC, Lippi G, Poli G, Berntorp E. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007; 13: 516.
  • 21
    Inoue T, Shima M, Takehyama M, Matsumoto T, Mishiya K, Tanaka I, Sakurai Y, Giddings JC, Yoshioka A. Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor. Haemophilia 2006; 12: 11013.
  • 22
    Shi Q, Kuether EL, Schroeder JA, Perry CL, Fahs SA, Cox Gill J, Montgomery RR. Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo. J Thromb Haemost 2012; 10: 232837.
  • 23
    Gewirtz J, Thornton MA, Rauova L, Poncz M. Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. J Thromb Haemost 2008; 6: 11606.
  • 24
    Hay CM, Dimichele DM, on behalf of International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 133544.